The FDA approved a new daily HIV pill from Gilead. The press release says it's designed to simplify treatment. The fine print says it's aimed at people already doing well on Biktarvy who want to switch to a new treatment.
Read that again. People doing well. Who want to switch.
Gilead looked at patients with controlled HIV on a single-tablet regimen and asked the most important question in pharmaceutical history: what if we made them take a different single tablet instead?
This is the corporate equivalent of a car dealership calling you to say your lease is up and they have the perfect new vehicle for you. It's the same car. Different color. Higher payment.
The FDA signed off on this. Somewhere in Silver Spring, Maryland, a regulator reviewed clinical data showing that patients stable on one pill could theoretically remain stable on a slightly different pill and thought, yes, the American people need this option.
Retail traders saw the news and immediately started Googling whether Gilead is undervalued. They're building discounted cash flow models in Excel. They're dividing market cap by revenue and nodding like they've discovered something. One guy on Reddit just posted that this approval could be a catalyst for re-rating the stock because it demonstrates pipeline momentum.
The pipeline momentum is a pill for people who don't need a new pill.
Gilead's investor relations team is probably drafting talking points about expanded treatment options and patient choice. The clinical team is probably relieved they don't have to explain why switching from one effective medication to another equally effective medication constitutes innovation.
This is what pharma does when the patents are running out and the generics are circling. Rebrand. Reformulate. Get the FDA to call it new. Bill insurance companies accordingly. Pray nobody notices you're just rotating inventory.
The pill simplifies treatment the same way changing your email password simplifies cybersecurity.
Photo by on Unsplash
Leave a Comment